“IMMU's Trodelvy has already completed phase 3 a
Post# of 145746
Bottom Line: Leronlimab is a few years behind IMMU’s cancer dug in terms of trials and approval. Comparing CYDY to IMMU at this point, in terms of cancer, is not accurate. Give the drug cancer trials another year or two, and then we might be able to compare.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)